CellChorus to present at the MIT Health Science Technologies Conference
The 2022 MIT Health Science Technologies Conference will focus on the future of cell & gene therapies
PRESS RELEASE
HOUSTON, Texas — March 1, 2022 — CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how thousands of individual cells perform over time, announced today that it will present at the 2022 MIT Health Science Technologies Conference: The Future of Cell & Gene Therapies.
The MIT Health Science Technologies Conference is focused on elucidating challenges that the health sciences industry is facing and explore potential solutions coming from academic research and startup endeavors, from early discovery through manufacturing technologies, to clinical studies and beyond.. The conference will take place at the Boston Marriott Cambridge on April 12, 2022.
“As we increasingly rely on cell-based therapeutics to provide life-changing therapies to patients, developers and manufacturers of these novel therapies need to understand which of their cells perform best, and why,” said Daniel Meyer, CEO of CellChorus. “We are excited to share our experiences and learn from other innovators that are developing new technologies and approaches for the discovery, development, manufacturing and delivery of novel therapies for patients.”
Additional details can be found below:
Event: 2022 MIT Health Science Technologies Conference: The Future of Cell & Gene Therapies
Date: Tuesday, April 12, 2022
Location: Boston Marriott Cambridge, 50 Broadway, Cambridge, MA 02142
Registration: Available at this link
An example of the CellChorus TIMING platform showing a single well out of 1000s on the CellChorus array, including a T cell with specificity for the Spike protein (position 424-433) of the novel coronavirus SARS-CoV-2 (COVID-19) from a recovered patient that exhibits serial killing of cells expressing the spike protein.
About CellChorus
CellChorus is the leader in applying artificial intelligence to visually evaluate how thousands of individual immune cells, such as T cells and NK cells, perform over time. The company applies Time lapse Imaging Microscopy in Nanowell Grids (TIMING™) with neural network-based artificial intelligence (AI) to identify cells and evaluate their activity, including how they move, activate, kill and survive. The patent-protected CellChorus platform can link TIMING data and insights with information from other analysis modalities such as single-cell RNA sequencing and flow cytometry to provide a comprehensive understanding of cellular function, state and phenotype for the life sciences industry. Please visit cellchorus.com for more information.
Company Contact:
Daniel Meyer
Chief Executive Officer
CellChorus Inc.
TIMING@cellchorus.com
SOURCE CellChorus Inc.